Intraductal Papillary Mucinous Neoplasm with Pancreatogastric Fistula

Hideaki Takahashi1,2, Yasushi Adachi1, Kazunari Nakahara2, Takefumi Kikuchi1, Hiroaki Mita3, Masahiro Nakamura3, Yukinari Yoshida1, Yasuo Kato1, Yoshifumi Ishii4 and Takao Endo3

Abstract:
We herein report a rare case of intraductal papillary mucinous neoplasm with a pancreatogastric fistula in an elderly Japanese man admitted to our hospital. The pancreatogastric fistula was confirmed using endoscopic retrograde pancreatography via a cannulated guidewire placed in the stomach. Six months after admission, the patient was diagnosed with intraductal papillary mucinous carcinoma. A pancreatogastric fistula is generally a rare complication of intraductal papillary mucinous neoplasm. It was caused by mechanical penetration in this case. Interestingly, we also observed endoscopic and histochemical mucosal changes in the fistula.

Key words: intraductal papillary mucinous neoplasm, intraductal papillary mucinous carcinoma, pancreatogastric fistula, mechanical penetration, endoscopic retrograde cholangiopancreatography

(Intern Med 60: 1211-1215, 2021)
(DOI: 10.2169/internalmedicine.5889-20)

Introduction

In 1982, Ohashi et al. (1) reported the first four cases of mucus-producing pancreatic carcinoma having a favorable prognosis. After considerable research, the disease concept of intraductal papillary mucinous neoplasm (IPMN) was established in the mid-1990s. In 2006, to clarify the morphological and pathological features, the International Association of Pancreatology proposed an international consensus guideline for the management of IPMN and pancreatic mucinous cystic neoplasm (2). This guideline was revised in 2012 (3) and 2017 (4).

We herein report a rare case of IPMN with a pancreatogastric fistula diagnosed by an endoscopic biopsy and discuss the relationship between IPMN and pancreatogastric fistula. Interestingly, we observed endoscopic and histological mucosal changes in the fistula during its transformation from intraductal papillary mucinous adenoma (IPMA) to intraductal papillary mucinous carcinoma (IPMC) (5).

Case Report

An 83-year-old Japanese man with a history of prostate cancer who had suffered cerebral infarction 2 months prior was transferred to our hospital for rehabilitation. Laboratory investigations revealed anemia (hemoglobin, 10.8 g/dL) with an elevated platelet count and erythrocyte sedimentation reaction. The carbohydrate antigen 19-9 (CA19-9) and carcinoembryonic antigen (CEA) levels in the blood were moderately elevated (439.4 U/mL and 8.6 ng/mL, respectively).

Abdominal ultrasonography revealed a pancreatic tumor. Esophagogastroduodenoscopy (EGD) showed an ulcerative lesion with mucin excretion on the posterior wall of the upper gastric corpus and an enlarged ampulla of Vater with a patulous orifice and mucin excretion. EGD also showed a...
fish egg-like mucosal lesion in the fistula (Fig. 1A). Contrast-enhanced computed tomography (CT) showed a low-density non-enhanced mass lesion in the pancreatic body and the tail. In addition, the existence of a pancreato-gastric fistula was confirmed (Fig. 1B). Endoscopic ultrasonography revealed concordant findings, including a cystic lesion, the presence of solid tumor and mural lesion, and fistula formation (Fig. 1C).

A pathological examination of the biopsy specimen of the fistula showed irregular papillary proliferation lined with mucus-producing columnar epithelial cells with moderate cellular atypia (Fig. 2A). Mucin (MUC1), MUC5AC, and MUC6 were highly expressed on the papillary portion of the tumor, but MUC2 and caudal type homeobox 2 (CDX2) proteins were undetected. In the papillary portion of the tumor, the Ki-67 expression was mild, and the p53 expression was scarce (Fig. 2B, C). Furthermore, endoscopic retrograde cholangiopancreatography showed a dilated main pancreatic duct with leakage of contrast medium into the gastric corpus (Fig. 3A). In addition, the pancreatogastric fistula was con-
tologically diagnosed with IPMC. Although there was no histopathological evidence of malignancy in the first biopsy, we suspected malignancy at the beginning of admission because of the rapidly progressive course over several months and the presence of liver metastasis on contrast-enhanced CT (Fig. 4). It was suggested that the biopsied portion of the tumor in the interior of the fistula had been invaded and replaced with pre-existing IPMC. By day 190, the disease had gradually worsened, and the CA19-9 level had rapidly increased from 439.4 to 3,199 U/mL. Although the definitive findings of invasive carcinoma could not be confirmed by the second biopsied specimen, we diagnosed him with IPMN with associated invasive carcinoma because of the increased tumor marker levels and the presence of liver metastasis on contrast-enhanced CT (Fig. 4). We suspected malignancy at the beginning of admission because of the rapidly progressive course over several months and the presence of liver metastasis on contrast-enhanced CT (Fig. 4). It was suggested that the biopsied portion of the tumor in the interior of the fistula had been invaded and replaced with pre-existing IPMC. By day 190, the disease had gradually worsened, and the CA19-9 level had rapidly increased from 439.4 to 3,199 U/mL. Although the definitive findings of invasive carcinoma could not be confirmed by the second biopsied specimen, we diagnosed him with IPMN with associated invasive carcinoma because of the increased tumor marker levels and the presence of liver metastasis and regional adenopathy.

The patient ultimately died eight months after admission from multiple organ failure aggravated by IPMN with associated invasive carcinoma.

Figure 3. Findings of endoscopic retrograde cholangiopancreatography. A: Endoscopic retrograde cholangiopancreatography showing the main pancreatic duct and pancreatic gastric fistula. A guidewire was inserted into the stomach via the pancreatic gastric fistula. B: Endoscopically confirmed guidewire placement in the stomach.

Figure 4. Follow-up imaging findings. A: Abdominal computed tomography showing gradual enlargement of the pancreatic gastric fistula and pancreatic cystic lesion during follow-up. In addition, there were several metastatic lesions in the liver along with dilatation of the intrahepatic bile duct. B: Compared with the previous esophagogastroduodenoscopy findings, the mucous membrane was irregular, and the fish egg-like appearance of the fistula had disappeared.
To our knowledge, there have been 8 published reports comprising 15 cases of IPMN with pancreatogastric fistulas (Table) (6-13). Koizumi et al. (12) reported that the duodenum (24 cases, 59%), common bile duct (21 cases, 51%), and stomach (7 cases, 17%) were the organs most frequently affected by fistula formation. Kobayashi et al. (6) observed fistula in other organs in 18 of 274 (6.6%) patients, 10 of whom had main-duct IPMN, 8 branch-duct IPMN, and 8 pancreatogastric formation. Given the CT and endoscopic ultrasonography findings, our case had main-duct IPMN with a pancreatogastric fistula. Kobayashi et al. (6) noted mucin-marker expression, and 94% of IPMN cases with pancreatogastric fistula had intestinal-type tumors. According to the immunohistological staining findings, the present case was one of pancreatobiliary type tumor, which is rare among cases of IPMN with pancreatogastric fistulas.

Two factors have been reported to contribute to the pathogenesis of fistula formation, namely direct tumor invasion and increased mechanical force caused by elevated pressure in the pancreatic duct (6, 14). However, some studies have reported that 41-67% of patients with pancreatogastric fistula had mechanical penetration without tumor invasion around the fistula (6, 16). In the present case, we believe that the mechanical force contributed to fistula formation because there was scant evidence of malignancy or invasion
around the fistula.

The 5-year survival rates in patients with non-invasive and invasive IPMN have been reported to be 85-100% and 25-65%, respectively (17, 18). Furthermore, the 5-year survival rates in patients with non-invasive papillary adenocarcinoma, all types of IPMC, and common-type pancreatic adenocarcinoma have been shown to be 100%, 71%, and 10%, respectively (6). Therefore, the prognosis of non-invasive IPMN is more favorable than that of invasive IPMN. However, in the same study, the median survival duration of all IPMN patients with fistula formation was 16 months (6), and they had a worse prognosis than those with IPMC. In our case, despite the absence of the characteristics of IPMC in the initial biopsy, the high CA19-9 expression, rapid progression, and solid component on CT images were suggestive of IPMC somewhere else in the pancreas.

In conclusion, we report a rare case of pancreatobiliary-type IPMN with pancreatogastric fistulas. Reports of IPMN with pancreatogastric fistulas are rare, but we have described the changes in the endoscopic, pathologic, and clinical characteristics of IPMN over the natural course of such a case.

We could not obtain informed consent from the patient’s relatives after his death because of ethical concerns. We were also unable to obtain informed consent while the patient was alive because of ethical concerns.

The authors state that they have no Conflict of Interest (COI).

Hideaki Takahashi and Yasushi Adachi contributed equally to this work.

References

1. Ohashi K, Murakami Y, Maruyama M, et al. Four cases of mucosecreting pancreatic cancer (in Japanese). Prog Digest Endosc 20: 348-351, 1982.
2. Tanaka M, Chari S, Adsay V, et al.; International Association of Pancreatology. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Panreatology 6: 17-32, 2006.
3. Tanaka M, Fernández-del Castillo C, Adsay V, et al.; International Association of Pancreatology. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Panreatology 12: 183-197, 2012.
4. Tanaka M, Fernandez-del Castillo C, Kamisawa T, et al.; International Association of Pancreatology. Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Panreatology 6: 738-753, 2017.
5. Basturk O, Hong SM, Wood LD, et al.; Baltimore Consensus Meeting. A revised classification system and recommendations from the Baltimore Consensus Meeting for neoplastic precursor lesions in the pancreas. Am J Surg Pathol 39: 1730-1741, 2015.
6. Kobayashi G, Fujita N, Noda Y, et al. Intraductal papillary mucinous neoplasms of the pancreas showing fistula formation into other organs. J Gastroenterol 45: 1080-1089, 2010.
7. Honda K, Kume K, Yamasaki M, Yoshikawa I, Otsuki M. Pancreatico-gastric fistulas due to intraductal papillary mucinous neoplasm (IPMN). Intern Med 47: 557-558, 2008.
8. Shimizu M, Kawaguchi A, Nagao S, et al. A case of intraductal papillary mucinous neoplasm of the pancreas rupturing both the stomach and duodenum. Gastrointest Endosc 71: 406-412, 2010.
9. Usato M, Nabeya Y, Miyazaki S, et al. Postoperative recurrence of an IPMN of the pancreas with a fistula to the stomach. World J Gastrointest Endosc 16: 349-351, 2010.
10. Jausset F, Delvaux M, Dumitriu D, et al. Benign intraductal papillary-mucinous neoplasm of the pancreas associated with spontaneous pancreatico-gastric and pancreatico-duodenal fistulas. Digestion 82: 42-46, 2010.
11. Hall TC, Garcea G, Rajesh A, Dennison AR. Pancreatogastric fistula secondary to intraductal papillary mucinous neoplasia: a case report and review of the literature. Ann R Coll Surg Engl 93: e32-e34, 2011.
12. Koizumi M, Sata N, Yoshizawa K, et al. Post-ERCP pancreatogastrostic fistula associated with an intraductal papillary-mucinous neoplasm of the pancreas--a case report and literature review. World J Surg Oncol 3: 70, 2005.
13. Goto N, Yoshioka M, Hayashi M, Itani T, Mimura J, Hashimoto K. Intraductal papillary-mucinous neoplasm of the pancreas penetrating to the stomach and the common bile duct. J Pancreas 13: 61-65, 2012.
14. Strous GJ, Dekker J. Mucin-type glycoproteins. Crit Rev Biochem Mol Biol 27: 57-92, 1992.
15. Kurihara K, Nagai H, Kasahara K, Kanazawa K, Kanai N. Biliopancreatic fistula associated with intraductal papillary-mucinous pancreatic cancer: institutional experience and review of the literature. Hepatogastroenterology 47: 1164-1167, 2000.
16. Kamisawa T, Su Y, Egawa N, Nakajima H, Tsuruta K, Okamoto A. Malignancies associated with intraductal papillary mucinous neoplasm of the pancreas. World J Gastroenterol 11: 5688-5690, 2005.
17. Niedergethmann M, Grützmann R, Hildenbrand R, et al. Outcome of invasive and noninvasive intraductal papillary-mucinous neoplasms of the pancreas (IPMN): a 10-year experience. World J Surg 32: 2253-2260, 2008.
18. Rust CP, Cleary KR, Staerkel GA, et al. Intraductal papillary mucinous neoplasms of the pancreas: effect of invasion and pancreatic margin status on recurrence and survival. Ann Surg Oncol 13: 582-594, 2006.

The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).

© 2021 The Japanese Society of Internal Medicine

Intern Med 60: 1211-1215, 2021